Armata Pharma (ARMP) – Company Press Releases
-
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update
-
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
-
Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit
-
Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update
-
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
-
Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference
-
Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023
-
Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus
-
Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
-
Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update
-
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
-
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics
-
Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy
-
Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update
-
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update
-
Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis
-
Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC
-
Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
-
Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage
-
Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update
-
Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update
-
Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections
-
Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus
-
Armata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update
-
Innoviva Reports First Quarter 2022 Financial Results
-
Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Private Placement with Innoviva
-
Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate Update
-
HATCHspaces®, NexCore Group, and Nuveen Real Estate to Convert 56,300 SF Industrial Building to Biomanufacturing in West Los Angeles
-
Armata Pharmaceuticals Announces Clearance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of AP-PA02 in Non-Cystic Fibrosis Bronchiectasis
-
Armata Pharmaceuticals to Participate in Two Upcoming Investor Conferences
-
Innoviva Reports Fourth Quarter 2021 Financial Results
-
Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company's Bacteriophage Development
-
Armata Pharmaceuticals Provides Update on Pseudomonas Respiratory Programs
-
Armata Pharmaceuticals Provides Regulatory and Clinical Update Reflecting Sustained Progress Across Key Phage Therapeutic Development Programs
-
Armata Pharmaceuticals Announces Third Quarter Results and Provides General Corporate Update
-
Armata Pharmaceuticals to Present at the 2021 World Antimicrobial Resistance Congress
-
Armata Enters Lease to Build State-of-the-Art R&D and GMP Manufacturing Facility
-
Cystic Fibrosis Foundation Makes Equity Investment in Armata Pharmaceuticals
-
Armata Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
-
Armata Pharmaceuticals Announces Second Quarter Results and Provides General Corporate Update
-
Armata Pharmaceuticals Announces Chief Executive Officer Transition
-
Armata Pharmaceuticals to Present at the Ladenburg Thalmann 2021 Healthcare Conference
-
Armata Pharmaceuticals Announces First Quarter Results and Provides General Corporate Update
-
Innoviva Reports First Quarter 2021 Financial Results
-
Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Results and Provides General Corporate Update
-
Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $20 Million Private Placement with Innoviva
-
Armata Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference
-
Innoviva Reports Fourth Quarter 2020 Financial Results
-
Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company's Bacteriophage Development Programs
-
Armata Pharmaceuticals Announces the Addition of Robin C. Kramer to its Board of Directors
Back to ARMP Stock Lookup
